Mangalam Drug & Chem Ltd
NSE: MANGALAM · Pharmaceuticals · sector
₹28.20NSE close 2026-10-26
Key numbers
Market cap₹45 cr
Price₹28.20
52w high / low₹72 / ₹23
P/E–Sector median 27.9x
P/B0.4xSector median 2.9x
Book value₹65.1
Dividend yield–Sector median 0.48%
ROE-30.4%Sector median 11.7%
ROCE-12.7%Sector median 12.3%
OPM-3.9%Sector median 14.0%
Debt / equity1.02xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-1.7x
Current ratio0.79x
Sales growth 3y-14.6%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹1 cr vs borrowings ₹105 cr (FY26): borrowings are higher by ₹105 cr.
- Operating profit covered interest -1.7x in the last 12 months.
- No promoter shares are pledged.
- Promoter holding fell by 14.65 percentage points in a year, to 35.65% (2026-09-30).
- Operating cash flow was below net profit in 1 of the last 5 years (FY24).
- Net loss in 5 of the last 8 quarters.
- Revenue was higher than a year earlier in 0 of the last 4 quarters.
- Debtor days went from 28 (FY24) to 63 (FY26).
- No dividend in the last 5 financial years.
- Price ₹28.20 on 2026-10-26: -60.8% from the 52-week high, +23.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹127.69 · low ₹24.00
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 80 | 89 | 73 | 57 | 50 | 58 | 67 | 57 |
| EBITDA | 9 | 9 | 10 | -4 | -3 | -1 | -6 | 1 |
| OPM % | 10.9% | 9.9% | 13.9% | -7.8% | -5.7% | -2.4% | -8.4% | 1.6% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 3 | 1 | 0 | -14 | -7 | -10 | -13 | -8 |
| EPS (₹) | 1.70 | 0.81 | 0.04 | -8.72 | -4.64 | -6.21 | -8.48 | -4.83 |
| Revenue YoY | -38.0% | -34.1% | -7.9% | -0.4% | ||||
| Profit YoY | -373.2% | -862.8% | -22,466.7% | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 451 | 372 | 369 | 318 | 232 | 232 |
| EBITDA | 49 | 26 | 17 | 36 | -15 | -9 |
| Net profit | 20 | 1 | -9 | 7 | -44 | -38 |
| EPS (₹) | 12.42 | 0.80 | -5.73 | 4.25 | -28.05 | -24.16 |
| Revenue growth | -17.5% | -1.0% | -13.7% | -27.1% | -22.3% | |
| Profit growth | -93.5% | -814.2% | – | -760.7% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -14.6% | -9.4% | -22.3% |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -48.4% (2y) | -57.7% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 152 | 136 | 149 | 103 |
| Borrowings | – | 68 | 88 | 81 | 105 |
| Cash & equivalents | – | 3 | 1 | 3 | 1 |
| Total assets | – | 360 | 333 | 366 | 315 |
| Fixed assets | – | 108 | 104 | 134 | 116 |
| Capital work in progress | – | 6 | 0 | 0 | 0 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 47 | 28 | 39 | 40 |
| Inventory | – | 137 | 124 | 139 | 103 |
| Payables | – | 97 | 66 | 91 | 76 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 31 | 40 | -11 | 43 | 4 |
| Cash from investing | -27 | -22 | 0 | -19 | -12 |
| Cash from financing | -2 | -17 | 0 | -22 | 6 |
| Capex | 28 | 28 | 0 | 20 | 12 |
| Free cash flow | 3 | 12 | -11 | 22 | -8 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 0.8% | -6.7% | 4.5% | -43.1% |
| ROCE % | – | 6.8% | 1.3% | 8.6% | -15.5% |
| Debtor days | – | 46 | 28 | 45 | 63 |
| Inventory days | – | 200 | 185 | 303 | 239 |
| Payable days | – | 141 | 98 | 199 | 177 |
| Cash conversion cycle (days) | – | 105 | 115 | 149 | 125 |
| Working capital days | – | 40 | 12 | 8 | -64 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 35.65% |
| FIIs | 0.11% |
| DIIs | 0.00% |
| Public (non-institutions) | 64.24% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 50.30% | 50.30% | 50.30% | 50.30% | 35.64% | 35.65% | 35.65% | 35.65% |
| Promoter group | % |
|---|---|
| Shree Rasbihari Trading & Investment Pvt Ltd | 6.21% |
| Shri Jb Pharma Private Limited | 6.00% |
| Govardhan Murlidhar Dhoot | 3.23% |
| Shree Kishoriju Trading & Investment Pvt Ltd | 3.21% |
| Brijmohan Murlidhar Dhoot | 3.08% |
| Shweta Govardhan Dhoot | 2.59% |
| Radhika Ajay Dhoot | 1.85% |
| Smita Aditya Dhoot | 1.85% |
| Ramniwas Ramdayal Dhoot | 1.74% |
| Raj Exports Pvt Ltd | 1.21% |
| Govardhan Murlidhar Dhoot | 0.98% |
| Rekha Govardhan Dhoot | 0.93% |
| Ajay Ramniwas Dhoot | 0.88% |
| Jyoti Brijmohan Dhoot | 0.66% |
| Aditya R. Dhoot | 0.56% |
| Public holders above 1% | % |
|---|---|
| Anish Dwivedi | 1.42% |
| Thakkalapalli Sampath Rao | 1.03% |
23,991 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| MANGALAM | ₹45 cr | – | 0.4x | -30.4% | -12.7% | -3.9% | -14.6% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2018-09-17 | Other | Annual General Meeting |
| 2017-12-21 | Dividend | Interim Dividend Re 0.50 Per Share |
| 2017-09-18 | Other | Annual General Meeting |
| 2016-09-22 | Other | Annual General Meeting (Book Closure Dates Revised) |
| 2015-08-26 | Other | Annual General Meeting |
| 2014-09-18 | Other | Annual General Meeting |
| 2013-09-17 | Other | Annual General Meeting |
| 2012-09-17 | Other | Annual General Meeting |
| 2011-09-20 | Other | Annual General Meeting |
| 2010-09-21 | Other | Annual General Meeting |
| 2009-09-17 | Other | Annual General Meeting |
| 2008-09-18 | Other | Annual General Meeting |
| 2007-09-18 | Other | Agm |
| 2006-09-19 | Other | Agm/Div-Re0.20 Per Share |
| 2005-08-30 | Dividend | Agm/Dividend-2% |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | MANGALAM |
| BSE code | 532637 |
| ISIN | INE584F01014 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.